» Articles » PMID: 24288397

Gadoxetic Acid-enhanced MRI for T-staging of Gallbladder Carcinoma: Emphasis on Liver Invasion

Overview
Journal Br J Radiol
Specialty Radiology
Date 2013 Nov 30
PMID 24288397
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the diagnostic performance of gadoxetic acid-enhanced MRI with an emphasis on the usefulness of the hepatobiliary phase (HBP) in T-staging of gallbladder carcinoma.

Methods: 66 patients with surgically confirmed gallbladder carcinoma underwent MRI. Two radiologists independently reviewed two sets of gadoxetic acid-enhanced MRI without and with the HBP. Local tumour spread was evaluated according to T-staging, and the results were compared with pathological findings. The diagnostic performance of two image sets to differentiate each T-stage was compared.

Results: The sensitivities of MRI with the HBP to differentiate T1 vs ≥ T2 lesions, ≤ T2 vs ≥ T3 lesions and ≤ T3 vs T4 lesions were 96.3%, 85.7% and 100% for Observer 1 and 92.6%, 95.2% and 100% for Observer 2, respectively (p<0.0001). By adding the HBP, the sensitivities to differentiate ≤ T2 vs ≥ T3 lesions were increased from 66.7% to 85.7% for Observer 1 and from 81.0% to 95.2% for Observer 2, although there was no significant difference (p>0.05). The overall accuracies for T-staging were increased from 80.3% to 86.4% for Observer 1, a statistically significant degree (p=0.046), and from 83.8% to 87.9% for Observer 2 (p>0.05). The k-value for the two observers indicated excellent agreement.

Conclusion: Gadoxetic acid-enhanced MRI provided acceptable diagnostic performance for T-staging of gallbladder carcinoma. Addition of the HBP aids in the detection of liver invasion.

Advances In Knowledge: In the T-staging of gallbladder carcinoma, gadoxetic acid-enhanced MRI with the HBP may enhance detection of liver invasion.

Citing Articles

Influence of visceral adipose tissue on the accuracy of tumor T-staging of gastric cancer in preoperative CT.

Wu D, Bian L, Wang Z, Ni J, Chen Y, Zhang L Jpn J Radiol. 2024; .

PMID: 39607533 DOI: 10.1007/s11604-024-01711-3.


Radiomics-based machine learning and deep learning to predict serosal involvement in gallbladder cancer.

Zhou S, Han S, Chen W, Bai X, Pan W, Han X Abdom Radiol (NY). 2023; 49(1):3-10.

PMID: 37787963 DOI: 10.1007/s00261-023-04029-2.


Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives.

Cassese G, Han H, Yoon Y, Lee J, Cho J, Lee H Diagnostics (Basel). 2022; 12(7).

PMID: 35885535 PMC: 9320561. DOI: 10.3390/diagnostics12071630.


Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study.

Kuipers H, de Savornin Lohman E, van Dooren M, Braat A, Daams F, van Dam R Ann Surg Oncol. 2020; 28(2):835-843.

PMID: 32696306 PMC: 7801314. DOI: 10.1245/s10434-020-08858-z.


Determining the extent of cholecystectomy using intraoperative specimen ultrasonography in patients with suspected early gallbladder cancer.

Park J, Kim Y, Kim H, Yoon Y, Choi Y, Cho J Surg Endosc. 2015; 30(10):4229-38.

PMID: 26715022 DOI: 10.1007/s00464-015-4733-5.

References
1.
Hamrick Jr R, Liner F, Hastings P, COHN Jr I . Primary carcinoma of the gallbladder. Ann Surg. 1982; 195(3):270-3. PMC: 1352630. DOI: 10.1097/00000658-198203000-00005. View

2.
Dixon E, Vollmer Jr C, Sahajpal A, Cattral M, Grant D, Doig C . An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005; 241(3):385-94. PMC: 1356976. DOI: 10.1097/01.sla.0000154118.07704.ef. View

3.
Yoshimitsu K, Nishihara Y, Okamoto D, Ushijima Y, Nishie A, Yamaguchi K . Magnetic resonance differentiation between T2 and T1 gallbladder carcinoma: significance of subserosal enhancement on the delayed phase dynamic study. Magn Reson Imaging. 2012; 30(6):854-9. DOI: 10.1016/j.mri.2012.02.016. View

4.
Kim Y, Kim C, Han Y, Park G . Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?. Invest Radiol. 2010; 45(11):740-6. DOI: 10.1097/RLI.0b013e3181e943a7. View

5.
Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M . Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010; 256(3):806-16. DOI: 10.1148/radiol.10091334. View